<DOC>
	<DOCNO>NCT00427414</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , liposomal daunorubicin , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This clinical trial study well liposomal daunorubicin work treat patient HIV-related Kaposi 's sarcoma .</brief_summary>
	<brief_title>Liposomal Daunorubicin Treating Patients With HIV-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine effect liposomal daunorubicin citrate Kaposi 's sarcoma-associated herpes virus ( KSHV ) viral gene expression tumor patient HIV-related Kaposi 's sarcoma . Secondary - Determine effect drug KSHV viral gene expression peripheral blood mononuclear cell . - Determine effect drug KSHV viral load plasma . - Correlate viral load viral gene expression and/or tumor regression patient . OUTLINE : This multicenter , pilot study . Patients receive liposomal daunorubicin citrate IV day 1 15 . Treatment repeat every 4 week least 3 course absence disease progression unacceptable toxicity . Biopsies perform baseline treatment evaluate Kaposi 's sarcoma- associate herpes virus ( KSHV ) viral gene expression tumor skin tissue use reverse transcriptase-quantitative polymerase chain reaction . Blood sample collect baseline periodically treatment evaluate KSHV viral gene expression peripheral blood mononuclear cell viral load plasma . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Kaposi 's sarcoma ( KS ) involve follow : Skin Lymph node ( palpable disease ) Oral cavity Must ≥ 5 measurable , previously nonirradiated , cutaneous lesion use indicator lesion Must 2 lesion ≥ 5 x 5 mm accessible 4 mm punch biopsy Serologically confirm HIV positivity Concurrent antiretroviral therapy require , except patient exhaust available treatment option Must stable dose ≥ 4 week PATIENT CHARACTERISTICS : Life expectancy ≥ 3 month No neoplasia require cytotoxic therapy Not pregnant nursing Fertile patient must use effective barrier contraception 3 month completion study treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior anthracycline therapy At least 4 week since prior antineoplastic treatment KS , include follow : Chemotherapy ( 6 week nitrosoureas mitomycin C ) Radiotherapy Local therapy Biological therapy Investigational therapy At least 60 day since prior local therapy KS indicator lesion unless lesion clearly progress since treatment No concurrent investigational drug , cytotoxic chemotherapy , KSspecific treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>AIDS-related Kaposi sarcoma</keyword>
	<keyword>recurrent Kaposi sarcoma</keyword>
</DOC>